AnneSTsaoMD

Oncology • Houston, TX

Physician

Join to view full profile

Dr. Tsao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tsao's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
Indiana University School of MedicineResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TX State Medical License 2001 - 2026
WA State Medical License 2023 - 2026
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
AL State Medical License 2023 - 2024
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Start of enrollment: 2006 Aug 01
Completed
Phase 1
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Start of enrollment: 2006 Nov 01
Completed
Phase 2
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer Start of enrollment: 2007 Jan 01
Completed
Phase 2
Dasatinib in Resectable Malignant Pleural Mesothelioma Start of enrollment: 2008 Mar 12
Completed
Phase 1
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2005 Jan 01
Completed
Phase 2
Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134) Start of enrollment: 2013 Apr 01
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery Start of enrollment: 2017 Apr 05
Recruiting
Phase 2
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer Start of enrollment: 2017 Dec 06
Recruiting
Phase 1
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Start of enrollment: 2019 Mar 20
Active, not recruiting
Phase 2
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Start of enrollment: 2019 Sep 13
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell ...
Sinchita Roy-Chowdhuri, Haresh Mani, Adam H Fox, Anne Tsao, Lynette M Sholl
Cancer. 2024-12-15
S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma.
Anne S Tsao, Ming-Hui Hsieh, Marianna Koczywas, Janet Tu, Jonathan Riess
JTO Clinical and Research Reports. 2024-12-01
Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review.
Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2024-11-30

Lectures

Changing the Concurrent Chemotherapy-Radiation Paradigm: Can We Replace Chemotherapy with...
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothel...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Systemic treatment for unresectable malignant pleural mesothelioma
Tsao AS, Vogelzang N
http://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma
UpToDate, Wolters Kluwer Health - 2013-04-15

Press Mentions

ECOG-ACRIN Research Highlights at ASCO 2022May 27th, 2022
New Mesothelioma Immunotherapy Clinical Trial Opens at MD AndersonMay 11th, 2022
Raffit Hassan, MD, on Immunotherapy's Inroads in Malignant Pleural MesotheliomaMay 6th, 2022
Join now to see all

AnneSTsaoMD

Dr. Tsao is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.